EXPERIMENTAL IMMUNOLOGY
CD300LG improves the cytotoxic activity of CIK
Submission date: 2016-01-01
Final revision date: 2016-03-25
Acceptance date: 2016-04-18
Publication date: 2017-08-08
Cent Eur J Immunol 2017;42(2):117-122
KEYWORDS
ABSTRACT
To investigate the effect of CD300LG-γ induction on the cytotoxic activity of CIK. Eukaryotic expression plasmid hCD300LG-γ/pEGFP-C3, which can express human CD300LG-γ, was constructed and transfected into CHO cells by lipofectamine. The expression of CD300LG- was confirmed by immunofluorescence, RT-PCR, and Western Blot. To produce CIK cells, human peripheral blood mononuclear cells (PBMC) were isolated and induced, respectively, by cell lysates extracted from hCD300LG-γ/CHO cells, pEGFP-C3/CHO cells, and CHO cells, concurrently with the standard CIK inductive agent. The cytotoxic activity of these CIK cells against hCD300LG-γ/CHO cells, pEGFP-C3/CHO cells, CHO cells, and K562 cells was tested. The results showed that eukaryotic expression of plasmid hCD300LG-γ/pEGFP-C3 was constructed and transfected into CHO cells successfully. After being induced by cell lysates, the cytotoxicity of hCD300LG-γ/CHO-CIK was improved compared with the other CIK cells. In particular, the activity of killing pEGFP-C3/CHO and CHO cells was improved significantly. Meanwhile, the activity of hCD300LG-/CHO-CIK killing K562 was improved significantly compared with the other CIK cells. The results indicated that hCD300LG- induction can significantly improve the killing activity of CIK cells.
REFERENCES (20)
1.
Umemoto E, Tanaka T, Kanda H, et al. (2006): Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. J Exp Med 203: 1603-1614.
2.
Takatsu H, Hase K, Ohmae M, et al. (2006): CD300 antigen like family member G: A novel lg receptor like protein exclusively expressed on capillary endothelium. Biochem Biophys Res Commun 348: 183-191.
3.
Umemoto E, Takeda A, Jin S, et al. (2013): Dynamic changes in endothelial cell adhesion molecule nepmucin/CD300LG expression under physiological and pathological conditions. PLoS One 8: e83681.
4.
Jin S, Umemoto E, Tanaka T, et al. (2008): Nepmucin/CLM-9, an Ig domain-containing sialomucin in vascular endothelial cells, promotes lymphocyte transen-dothelial migration in vitro. FEBS Lett 582: 3018-3024.
5.
Xiao-dong P, Zhi-juan L, Chong-jie Z (2010): Nepmucin, a novel adhesion molecule. Int J Immunol 33: 79-84.
6.
Cavallaro U, Christofori G (2004): Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature Rev Cancer 4: 118-132.
7.
Hazan RB, Qiao R, Keren R, et al. (2004): Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155-163.
8.
Guo W, Giancotti FG (2004): Integrin signalling during tumor progression. Nat Rev Mol Cell Biol 5: 816-826.
9.
Kim JB, Islam S, Kim YJ, et al. (2000): N-cadherin extracellular repeat mediates epithelial to mesenchymal transition and increased motility. J Cell Biol 151: 1193-1206.
10.
Li LC, Chui RM, Sasaki M, et al. (2000): A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60: 873-876.
11.
Mialhe A, Levacher G, Champelovier P, et al. (2000): Expression of E-, P-, N-cadherins and catenins in human bladder carcinoma cell lines. J Urol 164: 826-835.
12.
Mueller S, Cadenas E, Schönthal AH (2000): p21 WAFL regulate sanchorage-independent growth of HCTll6 coloncarcinoma cells via E cadherin expression. Cancer Res 60: 156-163.
13.
Makrilia N, Kollias A, Manolopoulos L, et al. (2009): Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 27: 1023-1037.
14.
Rychly J, Nebe B (2006): Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des 12: 3799-3806.
15.
Zhai S, Xu H, Jiang X, et al. (2016): Expression Depression of CD300LG- in Human Pulmonary Carcinoma. Monoclon Antib Immunodiagn Immunother 35: in printed.
16.
DeVita VT Jr, Rosenberg SA (2012): Two hundred years of cancer research. N Engl J Med 366: 2207-2214.
17.
Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. (1991): Use of a SCID mouse/human lymphoma model to evaluate cytokine induced killercells with potent antitumor cell activity. J Exp Med 174: 139-149.
18.
Hontscha C, Borck Y, Zhou H, et al. (2011): Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-310.
19.
Jakel CE, Schmidt-Wolf IG (2014): An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther 14: 905-916.
20.
Nie Xin, Liu Kan-Feng, Teng Shao-Xia (2007): The anti-tumor development of CIK and its clinical application. China Pract Med 2: 106-108.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
